GlassScriptPhysician profile
Gerald Larochelle
NPI 1821091489
$24,330.07
in general payments reported to CMS, 2019-2025
58 companies · $3,243 in 2025
The $3,243 reported for 2025 was more than what 79% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,367 · 2020: $1,827 · 2021: $1,899 · 2022: $3,760 · 2023: $4,906 · 2024: $4,328 · 2025: $3,243.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12,477.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $4,332.08 | 2019-2025 | Evenity, Otezla, Prolia |
| Abbvie INC. | $3,562.28 | 2019-2025 | |
| Janssen Biotech, INC. | $2,508.19 | 2019-2025 | Tremfya, Simponi Aria, Remicade |
| Ucb, INC. | $1,541.55 | 2019-2025 | Bimzelx, Cimzia |
| Novo Nordisk INC | $1,450.45 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $919.90 | 2019-2025 | Benlysta, Arexvy, Shingrix |
| Lilly USA, LLC | $790.43 | 2019-2024 | Jardiance, Mounjaro, Baqsimi |
| Novartis Pharmaceuticals Corporation | $778.82 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $746.94 | 2019-2025 | Orencia |
| Horizon Therapeutics Plc | $617.01 | 2019-2023 | Tepezza, Krystexxa |
| Radius Health, INC. | $612.98 | 2019-2025 | Tymlos |
| Astrazeneca Pharmaceuticals LP | $603.66 | 2019-2024 | Saphnelo |
| Janssen Pharmaceuticals, INC | $549.63 | 2019-2022 | |
| Abbott Laboratories | $531.56 | 2021-2023 | Freestyle Libre 3 |
| Pfizer INC. | $448.17 | 2019-2025 |
Show all 58 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Antares Pharma, INC. | $320.30 | 2019-2022 | |
| Alexion Pharmaceuticals, INC. | $316.50 | 2023-2024 | Strensiq |
| Genentech USA, INC. | $310.54 | 2019-2024 | Actemra |
| Regeneron Healthcare Solutions, INC. | $244.75 | 2019 | |
| Sanofi-Aventis U.S. LLC | $226.69 | 2024 | |
| Calliditas Therapeutics US INC. | $217.25 | 2023-2024 | Tarpeyo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $208.61 | 2020-2025 | Ofev |
| Merck Sharp & Dohme LLC | $194.05 | 2019-2020 | |
| Dexcom, INC. | $180.57 | 2021-2023 | Dexcom G7 Gss (161) |
| Bayer Healthcare Pharmaceuticals INC. | $170.17 | 2022-2025 | |
| Celgene Corporation | $169.84 | 2019 | |
| Daiichi Sankyo INC. | $153.07 | 2021-2025 | Injectafer |
| Mallinckrodt Hospital Products INC. | $139.57 | 2020-2025 | Acthar |
| Genzyme Corporation | $136.70 | 2023 | |
| Ultragenyx Pharmaceutical INC. | $135.59 | 2019-2022 | |
| Grt US Holding, INC. | $127.97 | 2022 | |
| Beta Bionics, INC. | $124.84 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Xeris Pharmaceuticals, INC. | $109.44 | 2020-2024 | Gvoke Hypopen, Recorlev |
| Aurinia Pharma U.S., INC. | $104.67 | 2023-2024 | Lupkynis |
| Pacira Therapeutics, INC. | $79.37 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $63.01 | 2019-2024 | Rexulti |
| Valeritas, INC. | $56.77 | 2019 | |
| Mallinckrodt Enterprises LLC | $49.96 | 2019 | |
| Mannkind Corporation | $48.21 | 2019-2021 | |
| Madrigal Pharmaceuticals | $44.28 | 2025 | Rezdiffra |
| Amarin Pharma, INC. | $43.81 | 2020-2021 | |
| Corcept Therapeutics | $39.66 | 2019-2024 | Korlym |
| Shire North American Group INC | $35.47 | 2019 | |
| Insulet Corporation | $28.45 | 2020-2022 | |
| Arbor Pharmaceuticals, INC. | $27.29 | 2019 | |
| Averitas Pharma INC. | $24.11 | 2023 | Qutenza |
| Vital Connect, INC | $23.37 | 2024 | Vitalpatch Rtm |
| Medicomp INC | $23.20 | 2023 | Telepatch Cardiac Monitor |
| Teva Pharmaceuticals USA, INC. | $18.20 | 2024 | |
| Janssen Scientific Affairs, LLC | $17.16 | 2023 | Tremfya |
| Fresenius Kabi USA, LLC | $16.77 | 2025 | |
| Scilex Pharmaceuticals INC. | $16.34 | 2024 | |
| Kyowa Kirin, INC. | $15.75 | 2024 | Crysvita |
| Astellas Pharma US INC | $15.68 | 2020 | |
| Kiniksa Pharmaceuticals, LTD. | $14.99 | 2023 | Arcalyst |
| Takeda Pharmaceuticals U.S.A., INC. | $14.70 | 2023 | Trintellix |
| Eisai INC. | $14.67 | 2021 | |
| Boston Scientific Corporation | $14.08 | 2023 | Watchman Access System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gerald Larochelle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.